Receptos Flat In IPO

San Diego-based biopharmaceuticals developer Receptos is trading flat after its initial public offering, after pricing last night at $14.00 per share. The developer of biopharmaceuticals for treating immune and metabolic diseases priced at the low end of its estimated IPO range, which was $14.00 to $16.00 per share. The firm was trading around its open price as of 1:00PM ET. Receptos debuted this morning as RCPT on the Nasdaq Global Market. The firm's venture capital backers are ARCH Venture Partners, Flagship Ventures, Lilly Ventures Fund, Polaris Ventures, and Venrock Associates.